Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, 2-Period Crossover Study to Assess the Safety, Tolerability, and Effects of MK-0974 on Exercise Tolerance in Patients With Stable Angina
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Telcagepant (Primary)
- Indications Angina pectoris
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 18 Feb 2011 New trial record